These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 32451342)
101. Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea. Boof ML; Dingemanse J; Lederer K; Fietze I; Ufer M Sleep; 2021 Jun; 44(6):. PubMed ID: 33305817 [TBL] [Abstract][Full Text] [Related]
102. Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease. Boof ML; Dingemanse J; Brunke M; Esselmann A; Heymer P; Kestermann O; Lederer K; Fietze I; Ufer M J Sleep Res; 2021 Aug; 30(4):e13248. PubMed ID: 33417730 [TBL] [Abstract][Full Text] [Related]
103. Erratum to "Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder". Ann Neurol; 2020 Sep; 88(3):647-651. PubMed ID: 33464656 [No Abstract] [Full Text] [Related]
104. Lemborexant (Dayvigo) for the Treatment of Insomnia. Rhodes MA Am Fam Physician; 2021 Feb; 103(4):241-242. PubMed ID: 33587572 [No Abstract] [Full Text] [Related]
105. Lemborexant vs suvorexant for insomnia: A systematic review and network meta-analysis. Kishi T; Nomura I; Matsuda Y; Sakuma K; Okuya M; Ikuta T; Iwata N J Psychiatr Res; 2020 Sep; 128():68-74. PubMed ID: 32531478 [TBL] [Abstract][Full Text] [Related]
106. Daridorexant for the Treatment of Insomnia. Robinson CL; Supra R; Downs E; Kataria S; Parker K; Kaye AD; Viswanath O; Urits I Health Psychol Res; 2022; 10(3):37400. PubMed ID: 36045942 [TBL] [Abstract][Full Text] [Related]
107. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Zammit G; Dauvilliers Y; Pain S; Sebök Kinter D; Mansour Y; Kunz D Neurology; 2020 May; 94(21):e2222-e2232. PubMed ID: 32341187 [TBL] [Abstract][Full Text] [Related]
108. Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder. Dauvilliers Y; Zammit G; Fietze I; Mayleben D; Seboek Kinter D; Pain S; Hedner J Ann Neurol; 2020 Mar; 87(3):347-356. PubMed ID: 31953863 [TBL] [Abstract][Full Text] [Related]
109. Daridorexant treatment for chronic insomnia: a real-world retrospective single-center study. Fernandes M; Placidi F; Mercuri NB; Liguori C Neurol Sci; 2024 Jul; 45(7):3443-3448. PubMed ID: 38280086 [TBL] [Abstract][Full Text] [Related]
110. Daridorexant for the treatment of insomnia disorder: A systematic review and meta-analysis of randomized controlled trials. Jiang F; Li H; Chen Y; Lu H; Ni J; Chen G Medicine (Baltimore); 2023 Feb; 102(7):e32754. PubMed ID: 36800596 [TBL] [Abstract][Full Text] [Related]
111. Daridorexant: A new medication for insomnia in older adults? Molano JRV Neurology; 2020 May; 94(21):e2287-e2289. PubMed ID: 32451342 [No Abstract] [Full Text] [Related]
112. Daridorexant: First Approval. Markham A Drugs; 2022 Apr; 82(5):601-607. PubMed ID: 35298826 [TBL] [Abstract][Full Text] [Related]
113. [Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia]. Tanaka Y; Aoki I; Ishine T; Renger JJ; Winrow CJ; Hisada S Nihon Yakurigaku Zasshi; 2016 Jul; 148(1):46-56. PubMed ID: 27430679 [No Abstract] [Full Text] [Related]
114. Suvorexant (Belsomra) for insomnia. Med Lett Drugs Ther; 2015 Mar; 57(1463):29-31. PubMed ID: 25719996 [No Abstract] [Full Text] [Related]